SEEL — Seelos Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $3.98m
- $15.20m
- $2.20m
Annual cashflow statement for Seelos Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -51.3 | -19.1 | -66 | -73.5 | -37.9 |
| Non-Cash Items | 25.1 | 2.73 | 18.5 | 9.15 | 1.55 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 6.86 | -4.54 | -1.41 | 2.78 | 12.4 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -19.3 | -20.9 | -49 | -61.6 | -23.9 |
| Financing Cash Flow Items | — | — | — | -0.273 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 29.5 | 26.3 | 112 | -1.6 | 11.4 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 10.2 | 5.4 | 63.1 | -63.2 | -12.5 |